AGP Executive Report
Last update: 2 hours agoFDA Watch: The FDA has approved datopotamab deruxtecan (Dato-DXd) for metastatic triple-negative breast cancer in patients who can’t get PD-1/PD-L1 therapy, positioning it as a new first-line option after TROPION-Breast02 showed major progression-free and overall survival gains. EU Oncology: The CHMP backed a perioperative pembrolizumab combo for cisplatin-ineligible resectable muscle-invasive bladder cancer, while sacituzumab tirumotecan hit a key first-line PFS target in TNBC. Security & Tech: Microsoft is dealing with fallout from multiple actively exploited flaws, including Exchange Server issues and BitLocker bypass claims, with organizations urged to act fast. Geopolitics: Ukraine is pushing Europe to negotiate with Russia through a single, consolidated mediation format—no backchannel contacts with Putin. Berlin/Europe: Berlin’s Olympics bid is back in focus, while the week also brought fresh attention to how Germany handles sensitive cases and public trust.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
